DiaSys Corporation (AMEX:DYX) a global healthcare products company, announced today that it has signed three-year exclusive distribution agreements with Rochem Biocare for territories that cover Colombia, Peru, Ecuador and Panama. The agreements guarantee minimum orders of $1.46 million for the Company's parasitology and urine sediment workstations and consumable products over the three-year period. Rochem Biocare, which was founded in 1981, also represents Beckman Coulter, Becton Dickinson, Dade Behring and Instrumentation Laboratory.

Jose Puig, Sales Manager Latin America stated, "In addition to our recent agreement in Mexico and the award in Venezuela these new transactions that cover Colombia, Peru, Ecuador and Panama provide DiaSys Corporation with a network of capable, experienced diagnostic distributors in each market."

"DiaSys Corporation has now received three-year guaranteed minimum orders with DICIPA and Rochem Biocare and an award with Repreclin Lab of approximately $16 million in Latin America, announced within the last two months. The fully integrated parasitology system, completed in the first calendar quarter of 2005, is the only system of its kind and without competition. We will continue the roll out of this product line throughout Latin America as we position for sales into the rest of world markets", said Gregory Witchel, Chief Executive Officer.

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.

Back